Geron Selvein Launches PDRN-Based Treatment 'Selvein Injection'

Geroncelvein, a specialty pharmaceutical company based on 'Polideoxyribonucleotide (PDRN)', announced on the 17th the launch of its specialty drug 'Celvein Injection' for pain and inflammation treatment.

PDRN is a high value-added substance extracted from the sperm and testes of salmon and trout, used as a material for pharmaceuticals or medical devices. It is composed of substances more than 90% similar to human DNA, known for low side effects and excellent tissue regeneration effects, and is utilized in various fields.

The newly launched 'Celvein Injection' by Geroncelvein utilizes the anti-inflammatory and pain reduction mechanisms of PDRN to suppress inflammation-related factors and increase anti-inflammatory factors, thereby simultaneously addressing inflammation and pain. Additionally, it has tissue regeneration effects that regenerate damaged tissues, enabling fundamental treatment and eliminating the need for excessive surgery through medication, according to the company.

In particular, the ingredients of Celvein Injection are substances naturally present in the human body, and safety has been confirmed through clinical trials. Geroncelvein plans to first introduce Celvein Injection, which can be used in various fields such as dentistry, as a pain and inflammation treatment in orthopedics to target the related market.

Furthermore, Geroncelvein plans to sell it as a skin booster used in dermatology. Amid the Ministry of Food and Drug Safety's ban this year on the use of skin boosters approved as cosmetics for procedural use, PDRN-based products are the only ones that can be used as skin boosters in specialty pharmaceuticals. Accordingly, Geroncelvein is conducting business to enable the use of Celvein Injection tailored for skin booster purposes.

A company official stated, “Starting with the launch of Celvein Injection, we plan to diversify future products such as PN fillers in July and continuously release PDRN products.”

This content was produced with the assistance of AI translation services.